NEWS

Noncontrast CT vs CT Perfusion or MRI Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion

A complex right MCA bifurcation aneurysm

The CLEVER Study – continued evolution of a trusted device

FRED X surface treatment impact on future INR strategies

Day 3 report of LINNC Paris 2022!

25 years of discussions for the INR community

Percutaneous embolization of a lymphatic sac tumor

LINNC Paris 2022 – DAY 1

Vesalio announces oversubscribed class A financing

Nashville, TN – (May 18, 2022) – Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures.

Vesalio Announces the Completion of Enrollment in Its FDA IDE Clinical S...

Nashville, TN May 11, 2022 --(  PR.com  )-- Vesalio is excited to announce the completion of patient enrollment for the CLEAR(1) FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS).